Page last updated: 2024-08-21

dronabinol and Scleroderma, Diffuse

dronabinol has been researched along with Scleroderma, Diffuse in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Bloom, BJ; Chung, L; Constantine, S; de Vries-Bouwstra, J; Denton, CP; Dgetluck, N; Dinh, Q; Distler, O; Finzel, S; Frech, TM; Furst, DE; Gordon, J; Hsu, V; Hummers, L; Jankowski, T; Jun, JB; Kafaja, S; Khanna, D; Kuwana, M; Lee, EB; Leszcyzński, P; Levy, Y; Litinsky, I; Matucci-Cerinic, M; Mayes, M; Sandorfi, N; Simms, RW; Spiera, R; Steen, V; Stevens, W; White, B1

Trials

1 trial(s) available for dronabinol and Scleroderma, Diffuse

ArticleYear
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
    Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:9

    Topics: Cannabinoid Receptor Agonists; Dronabinol; Humans; Scleroderma, Diffuse; Scleroderma, Systemic; Severity of Illness Index; Skin; Treatment Outcome

2023